Is Teva (TEVA 0.10%) genuinely concerned about Biogen's (BIIB 2.41%) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.
